非霍奇金淋巴瘤合并糖尿病患者的治疗体会  

Therapy experience in NHL patients with diabetics

作　　者：沈丽达[1] 张灿珍[1] 任宏轩[1] 李云霞[1] 邓明佳[1] 

机构地区：[1]云南省肿瘤医院肿瘤内一科,云南省肿瘤化疗研究中心,昆明650118

出　　处：《肿瘤研究与临床》2006年第6期391-392,共2页Cancer Research and Clinic

摘　　要：目的探讨非霍奇金淋巴瘤合并糖尿病患者的激素使用问题。方法对40例合并糖尿病的非霍奇金淋巴瘤患者用含泼尼松(PDN)的方案进行化疗,比较使用PDN前后的血糖变化,调整降糖药物,同时观察并发症。结果患者入院时空腹血糖(6.1±1.3)mmol/L,化疗后血糖(6.5±1.2)mmol/L,化疗前后血糖比较差异无统计学意义;化疗过程中降糖药用量略增加;所有患者无并发症发生。结论在有效控制血糖的情况下,非霍奇金淋巴瘤合并糖尿病的患者可常规使用PDN。Objective Discuss therapy problems in NHL patients with diabetics. Methods 40 NHL patients with diabetics are treated with chemotherapy containing prednisone. Compare the blood sugar before using prednisone with the one after that, regulate medicines of reducing glucose and at the same time observe the syndromes. Results Limosis blood sugar of patients just in hospital is （6.1±1.3） mmol/L, and after chemotherapy it becomes （6.5±1.2） mmol/L. There is no significant difference between them. Conclusions On the basis of controlling blood sugar effectively, patients with NHL combining diabetics can use prednisone as normal.

关 键 词：非霍奇金淋巴瘤 糖尿病 泼尼松 

分 类 号：R733.1[医药卫生—肿瘤] R587.1[医药卫生—临床医学]